Compare CUE & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CUE | ENTX |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.0M | 147.4M |
| IPO Year | 2017 | 2015 |
| Metric | CUE | ENTX |
|---|---|---|
| Price | $3.99 | $3.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $88.00 | $9.75 |
| AVG Volume (30 Days) | ★ 304.8K | 270.3K |
| Earning Date | 11-16-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.11 | N/A |
| EPS | N/A | ★ 0.33 |
| Revenue | ★ $27,466,000.00 | $42,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.12 |
| Revenue Growth | ★ 195.75 | N/A |
| 52 Week Low | $0.17 | $0.91 |
| 52 Week High | $45.50 | $4.20 |
| Indicator | CUE | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 23.00 | 55.68 |
| Support Level | $0.22 | $2.76 |
| Resistance Level | $33.95 | $3.52 |
| Average True Range (ATR) | 2.70 | 0.19 |
| MACD | -1.38 | -0.01 |
| Stochastic Oscillator | 6.25 | 42.54 |
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.